Development of Monoclonal Antibody-Based EIA for Tetranor-PGDM which Reflects PGD₂ Production in the Body

Figure 2

Analysis of tetranor-PGDM in urine. (a) Lipids for cross-reactivity test of tetranor-PGDM. (b) Inhibition curves for tetranor-PGDM, tetranor-PGEM, tetranor-PGAM, and tetranor-PGFM. Linearity of dilution curves for artificial urine samples before (c) and after (d) solid-phase extraction. The artificial urine sample with a high tetranor-PGDM level was diluted stepwise with the assay solution.

(a)

(b)

(c)

(d)